Literature DB >> 4039599

Tinidazole milk excretion and pharmacokinetics in lactating women.

G R Evaldson, S Lindgren, C E Nord, A T Rane.   

Abstract

Five women undergoing acute Caesarean section were given an i.v. dose of 1600 mg tinidazole preoperatively as prophylaxis against anaerobic infection. Blood and breast milk samples were collected at 8 and 4 h intervals, respectively, for 120 h. Tinidazole concentrations were measured by means of high performance liquid chromatography (h.p.l.c). The concentration of tinidazole in breast milk was highly related to the concentration in serum (r = 0.969). Tinidazole concentrations in serum declined monoexponentially with an average half-life of 11.4 h (range 8.7-13.1). The milk/serum concentration ratio varied between 0.62 and 1.39. Seventy-two hours after the Caesarean section the milk concentration exceeded 0.5 microgram/ml in only one woman. It may be calculated that at this time the maximum daily dose to the infant would be 0.1 mg/kg body weight (assuming 3.5 kg body weight and 400 ml milk consumed). We conclude that until tinidazole has been proven harmless to the neonate breast feeding following i.v. administration of 1600 mg should not be initiated earlier than 72 h after the dose.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4039599      PMCID: PMC1463824          DOI: 10.1111/j.1365-2125.1985.tb02676.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route.

Authors:  J Mattila; P T Männistö; R Mäntylä; S Nykänen; U Lamminsivu
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

2.  Internal fetal monitoring and maternal infection following cesarean section. A prospective study.

Authors:  R S Gibbs; P M Jones; C J Wilder
Journal:  Obstet Gynecol       Date:  1978-08       Impact factor: 7.661

3.  Post-cesarean section endometritis: causative organisms and risk factors.

Authors:  J R Middleton; J Apuzzio; M Lange; P Sen; J Bonamo; D B Louria
Journal:  Am J Obstet Gynecol       Date:  1980-05-01       Impact factor: 8.661

4.  The pharmacokinetics of intravenous tinidazole in man.

Authors:  C Charuel; J Nachbaur; A M Monro; J De Palol
Journal:  J Antimicrob Chemother       Date:  1981-10       Impact factor: 5.790

5.  Antimicrobial prophylaxis to prevent mixed bacterial infection.

Authors:  B F Polk
Journal:  J Antimicrob Chemother       Date:  1981-12       Impact factor: 5.790

6.  Metronidazole in breast milk.

Authors:  S H Erickson; G L Oppenheim; G H Smith
Journal:  Obstet Gynecol       Date:  1981-01       Impact factor: 7.661

7.  Blood and milk concentrations of metronidazole in mothers and infants.

Authors:  L Heisterberg; P E Branebjerg
Journal:  J Perinat Med       Date:  1983       Impact factor: 1.901

8.  The bacterial pathogenesis of infection following cesarean section.

Authors:  L C Gilstrap; F G Cunningham
Journal:  Obstet Gynecol       Date:  1979-05       Impact factor: 7.661

9.  Bacteremia in post-Cesarean section endomyometritis: differential response to therapy.

Authors:  G S DiZerega; M L Yonekura; K Keegan; S Roy; R Nakamura; W Ledger
Journal:  Obstet Gynecol       Date:  1980-05       Impact factor: 7.661

10.  Risk factors in cesarean section infection.

Authors:  L Hägglund; K K Christensen; P Christensen; C Kamme
Journal:  Obstet Gynecol       Date:  1983-08       Impact factor: 7.661

View more
  6 in total

Review 1.  Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.

Authors:  K C Lamp; C D Freeman; N E Klutman; M K Lacy
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

2.  Diagnosis and Management of Trichomonas vaginalis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines.

Authors:  Patricia J Kissinger; Charlotte A Gaydos; Arlene C Seña; R Scott McClelland; David Soper; W Evan Secor; Davey Legendre; Kimberly A Workowski; Christina A Muzny
Journal:  Clin Infect Dis       Date:  2022-04-13       Impact factor: 20.999

Review 3.  Drugs in human milk. Clinical pharmacokinetic considerations.

Authors:  H C Atkinson; E J Begg; B A Darlow
Journal:  Clin Pharmacokinet       Date:  1988-04       Impact factor: 6.447

Review 4.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-04       Impact factor: 6.447

5.  Metronidazole excretion in human milk and its effect on the suckling neonate.

Authors:  C M Passmore; J C McElnay; E A Rainey; P F D'Arcy
Journal:  Br J Clin Pharmacol       Date:  1988-07       Impact factor: 4.335

Review 6.  Systemic and Target-Site Pharmacokinetics of Antiparasitic Agents.

Authors:  Valentin Al Jalali; Markus Zeitlinger
Journal:  Clin Pharmacokinet       Date:  2020-07       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.